. Author manuscript; available in PMC: 2020 May 1.

Published in final edited form as: Gynecol Oncol. 2019 Feb 23;153(2):217–222. doi: 10.1016/j.ygyno.2019.02.011

Table 3.

Unadjusted and multivariable-adjusted association of CD3+ TILs or CD68+ TAMs and homologous recombination deficiency with OS.

HRD status	IHC score (high/low)	No.	Median OS (months)	HR (95% CI)	P value	Adjusted HR (95% CI)	P value
non-HRD	CD3 low	76	35.8	1 (Reference)	<0.001	1 (Reference)	<0.001
non-HRD	CD3 high	65	46.0	0.75 (0.52-1.0)		0.65 (0.44-0.95)
HRD	CD3 low	30	54.6	0.71 (0.45-1.13)		0.71 (0.44-1.14)
HRD	CD3 high	61	70.9	0.40 (0.27-0.61)		0.38 (0.25-0.59)

non-HRD	CD68 low	67	40.6	1 (Reference)	0.004	1 (Reference)	<0.001
non-HRD	CD68 high	74	35.1	1.04 (0.72-1.51)		0.89 (0.61-1.30)
HRD	CD68 low	31	84.3	0.55 (0.32-0.93)		0.56 (0.33-0.96)
HRD	CD68 high	60	65.4	0.59 (0.39-0.90)		0.54 (0.35-0.83)

Adjusted for age, stage, and optimal surgical cytoreduction. Stage 1 subjects (n=18) excluded. TIL, tumor infiltrating lymphocytes; TAM, tumor-associated macrophages; HRD homologous recombination deficient; OS, overall survival; IHC, immunohistochemistry.